title: Increased myeloperoxidase index and large unstained cell values can predict the neutropenia phase of cancer patients treated with standard dose chemotherapy.
abstract: OBJECTIVE
  The objective of this study was to better understand neutropenia induced by standard dose chemotherapy and to verify if there are any hematological parameters for defining the phase and possibly the duration of neutropenia.
  
  
  METHODS
  The kinetics of large unstained cells (LUCs) and lymphocytes was evaluated in 324 blood counts of 56 chemotherapy cycles through the use of a Technicon H2 or an ADVIA 120 hematology analyzer. Blood samples collected during the neutropenia phase were also studied by flow cytometry using a large panel of monoclonal antibodies. Parametric and nonparametric statistics were employed to compare the different variables analyzed. A linear regression between each variable before and after nadir and a simple linear correlation among the same variables in the neutropenic and recovery phase were performed.
  
  
  RESULTS
  The percentage of LUCs reaches the higher value at nadir and the difference between the mean value of prenadir and nadir is statistically significant (P <.01). The number of LUCs increases during the pre and postnadir phase. Lymphocytes number appears stable in the prenadir phase. The MPXI index increases in the prenadir phase and falls at nadir and this difference is statistically significant(P <.01). LUCs are correlated with blasts and CD34+ cells in the pre and postnadir phase, with CD3+/CD4+ cells in the prenadir phase, and with CD2+/CD56+ in the postnadir phase.
  
  
  CONCLUSIONS
  Our data have shown that the estimation of both percentage of LUCs and MPXI can predict the neutropenia phase and orient for its duration. The lymphocyte number may be regarded as a parameter of risk of fever after day 5 of chemotherapy and the number of blood CD34+ cells may be predicted by LUC count.
authors: Medical Oncology Unit, Regional Hospital of Rovigo, Rovigo, Italy.
authors: A
authors: A
authors: Bononi
authors: F
authors: F
authors: Lanza
authors: M
authors: M
authors: Dabusti
authors: M
authors: M
authors: Gusella
authors: G
authors: G
authors: Gilli
authors: D
authors: D
authors: Menon
authors: S
authors: S
authors: Toso
authors: G
authors: G
authors: Crepaldi
authors: B
authors: B
authors: Marenda
authors: V
authors: V
authors: Abbasciano
authors: E
authors: E
authors: Ferrazzi
mesh_terms: D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000032:analysis; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016130:Immunophenotyping; D007958:Leukocyte Count; D007962:Leukocytes / Q000737:chemistry / Q000187:drug effects* / Q000201:enzymology* / Q000473:pathology; D016014:Linear Models; D016131:Lymphocyte Subsets / Q000166:cytology / Q000187:drug effects / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced* / Q000201:enzymology*; D009195:Peroxidase / Q000378:metabolism*; D012016:Reference Values
chemical_list: D015703:Antigens, CD; D000970:Antineoplastic Agents; D009195:Peroxidase